| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to...
Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price tar...
Cogent Biosciences, Inc. ("Cogent") (Nasdaq: COGT), a biotechnology company focused on developing precision therapies f...
Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...